Clinical Trial Listing
Research Institute
- A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥ 12 to < 18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
- A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia
- Analysis of Genes Contributing to Heterotaxy Syndromes among Patients in PCH Heart Center
- The Use of EpiPen in Children with Urticaria Pigmentosa
- Creatine Usage Study
- Salivary Biomarkers as Predictor of Pediatric Traumatic Brain Injury Severity
- ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX
- ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, without Inhibitory Antibodies to Factor VIII or IX
- The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Institute of Child Health and Human Development (NICHD)
- LCH IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
- A Study to Monitor the Use of an Amino Acid-Based Infant Formula
- Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)
- A phase II, open-label, non-controlled, intra-patient dose-escalation study to characterize the pharmacokinetics after oral administration of eltrombopag with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects with Active Crohn’s Disease
- A Randomized Double-blind Pharmacokinetic Study of Ustekinumab in Pediatric Subjects with Moderately to Severely Active Crohn’s Disease
- Fractional Flow Reserve in Congenital Heart Disease Populations
- Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT: A Proposed Solution to Vitamin D Deficiency During Transplant
- Assessment of Liver and Metabolic Disease Risks in Children – Phase 1: Comparison of Advanced Ultrasound and MRI Techniques
- Tissue Engineering of Bioinspired, Personalized Neonatal Cardiac Patches to Improve Outcomes in Pediatric Patients with Congenital Heart Disease
- Pilot Psychosocial Screening Protocol in Children with Congenital Heart Disease
- Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT: A Proposed Solution to Vitamin D Deficiency During Transplant
- HLA antibody Evaluation and Platelet transfusions (HELP) in transplant for Sickle Cell Disease (SCD)
- NN7088-3908: An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of N8-GP in prophylaxis and treatment of bleeding episodes in previously untreated pediatric patients with severe haemophilia A
- Aflac ST1501, Phase I Study of Abemaciclib (LY2835219) inhibitor of Cyclin-dependent kinases 4 and 6 (Cdk4/6) in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Recurrent or Refractory Malignant Brain & Solid Tumors
- A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
- Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del CFTR Mutation
- Randomized, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of Oral Bacterial Extract for the prevention of wheezing lower respiratory tract illness (ORBEX)
- An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)
- Feasibility, Testing, and Protocol Refinement using Ultrasound and Magnetic Resonance Imaging with Healthy Volunteers
- Minimizing Parental Post Traumatic Stress Disorder in the NICU: Promotion of Grief Counseling
- A prospective randomized trial of antibiotic duration in post-appendectomy abscess
- Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A
- Leucovorin for the Treatment of Language Impairment in Children with Autism Spectrum Disorder
- International Pediatric Heart Failure Registry
- Phase III, open-label, single-dose, multi-center multinational trial investigating an serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B
- A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with Epidermolysis Bullosa (EB)
- Functional Outcomes following Musculoskeletal Coccidioidomycosis: Mid-Term Results at 2 Years
- Parent-Child Disclosures About Chronic Conditions
- The impact of pediatric skin disorders: The big study
- The role of executive function on health-related quality of life in children and adolescents with congenital or acquired heart disease who have undergone cardiothoracic surgery
- Implementation and evaluation of an eczema action plan
- An International, Mulit-Center, Open-label, Long Term Extension Study Evaluating the
Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex
(EBS) - Leucovorin for the Treatment of Language Impairment in Children with Autism Spectrum Disorder
Share this page